NCCN Guidelines® Insights

Acute Myeloid Leukemia, Version 2.2013
Featured Updates to the NCCN Guidelines

Margaret R. O’Donnell, MD; Martin S. Tallman, MD; Camille N. Abboud, MD; Jessica K. Altman, MD; Frederick R. Appelbaum, MD; Daniel A. Arber, MD; Eyal Attar, MD; Uma Borate, MD; Steven E. Coutre, MD; Lloyd E. Damon, MD; Jeffrey Lancet, MD; Lori J. Maness, MD; Guido Marcucci, MD; Michael G. Martin, MD; Michael M. Millenson, MD; Joseph O. Moore, MD; Farhad Ravandi, MD; Paul J. Shami, MD; B. Douglas Smith, MD; Richard M. Stone, MD; Stephen A. Strickland, MD; Eunice S. Wang, MD; Kristina M. Gregory, RN, MSN, OCN; and Maoko Naganuma, MSc

Abstract
These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocytic leukemia (APL) section, featuring recommendations for additional induction/consolidation regimens in patients with low- or intermediate-risk APL, and providing guidance on maintenance strategies for APL. (JNCCN 2013;11:1047–1055)

Please Note
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. The NCCN Guidelines® Insights highlight important changes in the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further understanding of these changes by summarizing salient portions of the panel’s discussion, including the literature reviewed.

The NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines are available at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2013, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Disclosures for the NCCN Acute Myeloid Leukemia Panel
Individual disclosures of potential conflicts of interest for the NCCN Acute Myeloid Leukemia Panel members can be found on page 1048.
Acute Myeloid Leukemia, Version 2.2013

NCCN: Continuing Education

Accreditation Statement
This activity has been designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer. There is no fee for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians. NCCN designates this journal-based CE activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This activity is accredited for 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NCCN designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-13-014-H01-P

Disclosure of Affiliations and Significant Relationships: NCCN Acute Myeloid Leukemia Panel
The following authors have no relevant financial interests to disclose: Dr. Appelbaum, Dr. Marcucci, Dr. Martin, Dr. Millenson, and Dr. Wang.

The following authors have disclosed the following relevant financial relationships:

Dr. Abboud: Advisory board member for ARIAD Pharmaceuticals, Inc and Teva Pharmaceutical Industries Ltd.
Dr. Altman: PI for ARIAD Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline; Millennium Pharmaceuticals, Inc.; Astellas Pharma Inc.; Clavis Pharma; Cyclacel Pharmaceuticals, Inc.; and CytRx Corporation. Conducted research for Eli Lilly and Company.
Dr. Arber: Consultant for US Diagnostic Standards.
Dr. Attar: Advisory board member Celgene Corporation and Jannsen Pharmaceuticals, Inc.
Dr. Borate: PI for GlaxoSmithKline.
Dr. Coutre: Advisory board member Celgene Corporation.
Dr. Damon: PI for Talon Therapeutics, Inc. and Sunesis Pharmaceuticals.
Dr. Lancet: PI and consultant for Celgene Corporation. Advisory board member for Spectrum Pharmaceuticals, Inc.
Dr. Maness: PI for Cyclacel Pharmaceuticals, Inc.
Dr. Moore: Investigator for ARIAD Pharmaceuticals, Inc.; Genentech, Inc.; and Novartis Corporation. Advisory board member for Amgen Inc.
Dr. O’Donnell: PI for NCI.
Dr. Ravandi: PI for Bayer AG; Celgene Corporation; Merck & Co., Inc.; and Sunesis Pharmaceuticals. Advisory board member for Bayer AG; Cephalon, Inc.; Eisai Inc.; Genzyme Corporation; Novartis Corporation; and Sunesis Pharmaceuticals.
Dr. Shami: Research support from Eisai Inc. and Genzyme Corporation. Speakers’ bureau member for ARIAD Pharmaceuticals, Inc. and Novartis Corporation.
Dr. Smith: Advisory board member for ARIAD Pharmaceuticals, Inc.; Clavis Pharma; and Teva Pharmaceutical Industries Ltd.
Dr. Stone: Data safety monitoring board member for Celgene Corporation and Sunesis Pharmaceuticals. Steering committee member for Celgene Corporation. Consultant for Novartis Corporation and ARIAD Pharmaceuticals, Inc. Advisory board member for Agios Pharmaceuticals and Seattle Genetics, Inc.
Dr. Strickland: Site investigator for GlaxoSmithKline; Novartis Corporation; Ambit Biosciences Inc.; Astellas Pharma Inc.; Celator Pharmaceuticals; Cyclacel Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC; and Sunesis Pharmaceuticals. Advisory board member for Boehringer Ingelheim GmbH and Sunesis Pharmaceuticals.
Dr. Tallman: Advisory board member for Genzyme Corporation.
The NCCN Guidelines Staff have no conflicts to disclose.

All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://educa
tion.nccn.org/node/28080; and 4) view/print certificate.

Release date: September 19, 2013; Expiration date: September 19, 2014

Learning Objectives:
Upon completion of this activity, participants will be able to:
• Integrate into professional practice the updates to the NCCN Guidelines for AML
• Describe the rationale behind the decision-making process for developing the NCCN Guidelines for AML

EDITOR: Kerrin M. Green, MA, Assistant Managing Editor, JNCCN—Journal of the National Comprehensive Cancer Network, has disclosed that she has no relevant financial relationships.

CE AUTHORS: Deborah J. Moonan, RN, BSN, Manager, CE Supporter Outreach, has disclosed the following relationships with commercial interests: AstraZeneca: Stockholder/Former Employee. Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, has disclosed that she has no relevant financial relationships. James Przak, RPh, Assistant Director, Continuing Education and Grants, has disclosed the following relationships with commercial interests: Bristol-Myers Squibb Company; Pension; Pfizer, Inc: Stockholder; United Healthcare Group: Stockholder; Johnson & Johnson: Stockholder. Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information and Operations, has disclosed no relevant financial relationships. Maoko Naganuma, MSc, Oncology Scientist/Medical Writer, has disclosed no relevant financial relationships.

Supported by educational grants from Eisai, Inc.; Millennium: The Takeda Oncology Company; Teva Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.; Celgene Corporation; Endo Pharmaceuticals and HealthTronics; Genentech; and ARIAD Pharmaceuticals, Inc.
Overview

Acute myeloid leukemia (AML) represents a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood and bone marrow. AML remains the most common form of acute leukemia diagnosed in adults, accounting for the largest number of annual deaths from leukemias in the United States. Approximately 14,590 new cases of AML and 10,370 deaths from the malignancy are estimated in 2013.\(^1\) The age-adjusted annual incidence rate of AML is 3.7 per 100,000 persons.\(^2\) Historically, acute promyelocytic leukemia (APL), which constitutes approximately 10% of AML cases, has been a particularly life-threatening subtype of AML, with a distinct morphology and clinical presentation.\(^3,4\) In a recent analysis of a data set from the SEER registry (1992–2007), the age-adjusted annual incidence of APL was 0.23 per 100,000 persons.\(^5\) The median age at APL diagnosis was 44 years, which is younger than

\(^*\)Several groups have published large trials with excellent outcomes. However, to achieve the expected results, one needs to use the regimen consistently through all components and not mix induction from one trial with consolidation from another.

\(^1\)Therapy-related APL is treated the same as de novo APL.

\(^2\)In patients with clinical and pathologic features of APL, start ATRA upon first suspicion of APL without waiting for genetic confirmation of the diagnosis. Early initiation of ATRA may prevent the lethal complication of bleeding. If cytogenetic and molecular testing do not confirm APL, discontinue ATRA and continue treatment as for AML.

\(^3\)Monitor for APL differentiation syndrome and coagulopathy; see Supportive Care (AML-C 2 of 2).

\(^4\)New data suggest similar outcomes in patients with low or intermediate risk.
that of patients with AML (median age, 67 years).²,⁶ Cytogenetically, APL is distinguished by the presence of the translocation t(15;17)(q22;q11.2), which involves fusion of the promyelocytic leukemia gene (PML) on chromosome 15 to the retinoic acid receptor alpha gene (RARA) on chromosome 17, resulting in the characteristic PML-RARA fusion gene.³,⁴ Although APL is highly curable in a large proportion of patients, it can be associated with severe coagulopathy, which remains the primary cause of early death from hemorrhagic events (especially during induction therapy).

**Induction/Consolidation Regimen for Low- and Intermediate-Risk APL**

The incorporation of all-trans retinoic acid (ATRA) and the use of risk stratification approaches have dramatically improved outcomes for patients with APL. Induction regimens with ATRA combined with anthracyclines, with or without cytarabine, show complete remission (CR) rates exceeding 90% in several large cooperative group trials.⁷-¹⁰ Using ATRA-based induction regimens followed by consolidation with regimens containing ATRA with anthracyclines, or cytarabine with anthracyclines, more than 80% of patients with APL can be cured.⁹⁻¹¹ Risk stratification is a major consideration in the treatment of APL (see AML-2, page 1049).¹² Patients with low- or intermediate-risk disease (WBC count ≤10,000/mcL) are typically treated with less-intensive consolidation regimens compared with those used to treat high-risk patients (WBC count >10,000/mcL), depending on the treatment protocol used. In the APL 2000 study (which included daunorubicin and cytarabine, but no ATRA, for consolidation), "standard-risk" (low- or intermediate-risk) patients received a lower dose of cytarabine during consolidation than the high-risk patients, and in the LPA 2005 and AIDA 2000 protocols (which
Another agent that has contributed to the evolution in APL therapy is arsenic trioxide (ATO). ATO promotes apoptosis of APL cells, and has been shown to act synergistically with ATRA. The addition of ATO as first-line consolidation therapy with ATRA and anthracycline (following standard induction with ATRA, anthracycline, and cytarabine) resulted in improved outcomes in the North American Intergroup trial. Induction regimens with ATO combined with ATRA (without chemotherapy) induced CR rates exceeding 90%, and recent studies have shown the efficacy of using ATO and ATRA during induction and consolidation (while omitting the use of chemotherapy) in patients with low- or intermediate-risk APL or those who cannot tolerate regimens containing anthracyclines.

In patients with low- or intermediate-risk APL, ATRA combined with ATO is a new addition to the standard of care based on results from a recent randomized trial that compared this regimen with the standard AIDA (ATRA plus idarubicin) regimen. In a phase III randomized trial of the Italian-German Cooperative Group, induction with ATRA combined with ATO was compared with the AIDA regimen in patients...
with newly diagnosed low- or intermediate-risk APL (N=162; APL-0406 study). Patients in Arm A received ATRA (45 mg/m²) plus ATO (0.15 mg/kg) daily until CR, then ATO 5 days per week for 4 weeks every 8 weeks for a total of 4 courses, and ATRA daily for 2 weeks every 4 weeks for a total of 7 courses. Patients in Arm B received the standard AIDA induction followed by 3 cycles of anthracycline-based consolidation combined with ATRA and then maintenance comprising low-dose chemotherapy and ATRA.11

The primary end point of this study was the 2-year event-free survival (EFS) rate. Among evaluable patients (n=156), CR rates after induction were not different between Arms A and B (100% vs 95%). Four deaths occurred in Arm B during induction therapy (2 of which were caused by differentiation syndrome). One death in Arm A and 3 in Arm B occurred during consolidation. Grade 3 or 4 neutropenia and thrombocytopenia lasting more than 15 days were significantly more frequent in Arm B compared with Arm A throughout the induction and consolidation cycles. Grade 3 or 4 hepatic toxicities occurred significantly more frequently in Arm A (63% vs 6%; P<.001).16 After a median follow-up of 34.4 months, the 2-year EFS rate was significantly higher in Arm A (97% vs 86%; P=.01 for noninferiority; P=.02 for superiority). The 2-year OS probability was also significantly higher in Arm A (99% vs 91%; P=.02). The 2-year cumulative incidence of relapse was not significantly different between the treatment arms (1% and 6%, respectively).16 This randomized study showed noninferiority of an ATRA- plus-ATO regimen compared with AIDA, which may allow for elimination of chemotherapy agents in the initial treatment of patients with non–high-risk APL.

NCCN Recommendations

For low- or intermediate-risk patients (WBC counts ≤10,000/mcL), the NCCN AML Panel recommends initial induction with either ATRA plus ATO16; ATRA plus idarubicin alone (AIDA regimen)13 (category 1); ATRA plus daunorubicin and cytarabine8,9,18 (category 1 for the French APL 2000 protocol9); or enrollment in a clinical trial (see AML-4, page 1050). The panel has positioned the ATRA-plus-ATO regimen first, based on results from the APL-0406 phase III randomized trial.16 The panel also recommends the ATRA-plus-ATO regimen for patients with high-risk disease who cannot tolerate anthracycline-containing therapy (see AML-2, page 1049).

The AIDA 2000 regimen may be positioned slightly higher than either the French APL 2000 or the North American Intergroup regimens because of the ease of administration and potentially decreased toxicity. However, all 4 of these regimens yield excellent results. Treatment protocols must be followed consistently throughout all components of the treatment phase, from induction to consolidation; induction regimens from one trial should not be used with consolidation regimens from another trial. Given data from recent studies that suggest similar outcomes for patients with low- or intermediate-risk disease, these patients are considered as a single category and treated with the same induction and consolidation regimens (see AML-4, page 1050).

Approaches to Maintenance Therapy in APL

The PML-RARA fusion gene can be quantitatively monitored using PCR assays to document disease burden and confirm postconsolidation molecular remission status in patients with APL. Considerable debate remains regarding the use and frequency of molecular monitoring and incorporation of maintenance therapy in the management of APL. Earlier studies have suggested the benefit of postconsolidation maintenance with ATRA (with or without chemotherapy) in terms of improved remission durations.7,18

The French APL93 trial randomized eligible patients (n=289) to 4 different maintenance regimens: no maintenance, intermittent ATRA, continuous chemotherapy (with 6-mercaptopurine and methotrexate), and the combination of ATRA with chemotherapy.19 Results showed decreased 2-year relapse rates with continuous chemotherapy (11.5% vs 27% with no chemotherapy) and ATRA (13.5% vs 25% with no ATRA). Results of long-term follow-up from this trial showed a beneficial effect of maintenance with intermittent ATRA and continuous chemotherapy, with an additive effect of the 2 modalities; the 10-year cumulative relapse rates with no maintenance, ATRA alone, continuous chemotherapy, and ATRA combined with chemotherapy were 43%, 33%, 23%, and 13%, respectively (P<.001).7 Patients at high risk (defined in this study as WBC count >5000/mcL) derived the most benefit from maintenance; the 10-year cumulative relapse rates among high-risk patients who
received no maintenance, ATRA alone, continuous chemotherapy, and ATRA combined with chemotherapy were 68%, 53%, 33%, and 21%, respectively (P<.001). No statistically significant difference in 10-year relapse rates was observed among patients with lower-risk disease, although the relapse rate dropped from 29% without maintenance to 11.5% with ATRA combined with chemotherapy. The 10-year OS rates with no maintenance, ATRA alone, continuous chemotherapy, and ATRA combined with chemotherapy, were 74%, 88%, 93%, and 94%, respectively (P<.001).7

The first North American Intergroup trial showed superior DFS outcomes for patients receiving maintenance ATRA compared with no maintenance.18 In this trial, patients were randomized to induction with chemotherapy (daunorubicin and cytarabine) or ATRA, and subsequently underwent a second randomization to either maintenance with ATRA or no maintenance (observation only). Consolidation therapy comprised the initial induction therapy regimen for course 1, and then daunorubicin and high-dose cytarabine for course 2. In this trial, molecular remission status was not assessed before randomization to maintenance. The 5-year DFS rates for the 4 randomization groups—chemotherapy induction plus observation, chemotherapy induction plus ATRA maintenance, ATRA induction plus observation, and ATRA induction plus ATRA maintenance—were 16%, 47%, 55%, and 74%, respectively.19 Although the incorporation of ATRA during induction and maintenance seemed to improve long-term remission durations, the role of maintenance therapy is less clear, because treatment strategies have evolved to incorporate ATRA or ATO into consolidation regimens. This is particularly a point of debate for low-risk patients who experience a molecular remission at the end of consolidation.

Data from other recent studies have not shown any long-term benefit with the use of maintenance therapy in patients who achieve molecular remission after consolidation.20,21 The Japanese APL97 randomized study evaluated the role of maintenance with intensified chemotherapy versus observation in patients in molecular remission after consolidation (n=1175).20 The estimated 6-year DFS rate was not significantly different between the chemotherapy maintenance and observation arms (63% vs 80%). The estimated 6-year OS rate was significantly lower with chemotherapy maintenance (86% vs 99%; P=.014), which the investigators attributed to the potential effects of chemotherapy maintenance on the development of secondary malignancies and on responses to subsequent (second-line) therapies.20

The AIDA 0493 trial initially randomized patients who were in postconsolidation molecular remission to 4 maintenance approaches (n=318): chemotherapy (with 6-mercaptopurine and methotrexate), ATRA alone, ATRA in combination with chemotherapy, or observation only.21,22 The study protocol was later amended to include only the 2 ATRA-containing maintenance arms (additional patients, n=268). ATRA was not given during consolidation. Among all patients experiencing molecular remission who were randomized to maintenance (n=586), the estimated 12-year molecular DFS rate was 71%.21 Among those randomized to the initial 4 maintenance arms, no significant differences in outcomes were observed between maintenance approaches; the estimated 12-year molecular DFS rates were 70% with chemotherapy, 69% with ATRA alone, 68% with ATRA combined with chemotherapy, and 69% with observation only. Among the patients who were enrolled and randomized to ATRA-containing maintenance arms following the protocol amendment, the estimated 10-year molecular DFS rates were 73% with ATRA alone and 74% with ATRA combined with chemotherapy. These studies showed that maintenance therapy provided no long-term benefit in patients with APL who experienced molecular remission after consolidation. With contemporary treatment strategies that incorporate ATRA and/or ATO into consolidation regimens, the role of maintenance becomes even less clear. The benefit of maintenance therapy likely depends on the regimens used during induction and consolidation therapies. Therefore, maintenance therapy must be used in conjunction with the treatment protocols in which it has been shown to confer benefit.

Further data from randomized trials are needed to address the question of maintenance. A phase III cooperative group trial (SWOG 0521) has been designed to examine the need for maintenance therapy (using the combination of ATRA, 6-mercaptopurine, and methotrexate) in patients with low- or intermediate-risk APL. In this ongoing trial, patients receive induction therapy with ATRA, daunorubicin, and cytarabine, followed by consolidation ther-
apy with ATO, ATRA, and daunorubicin. Patients are then randomized to receive maintenance therapy or no further treatment (observation only).

**NCCN Recommendations**

The NCCN AML Panel recommends that PCR be performed on a bone marrow sample at the completion of consolidation to document molecular remission (see AML-5, page 1051). It is at the discretion of the treating physician to determine the appropriate frequency of monitoring for individual patients. Subsequent monitoring by PCR can be performed on peripheral blood samples, although using marrow samples is a more sensitive monitoring technique and may indicate earlier signs of relapse. For patients with PCR-negative results after consolidation, ATRA maintenance (a 1- to 2-year course, which may be combined with 6-mercaptopurine and methotrexate) may be a reasonable approach, particularly for high-risk patients. For patients with low-risk disease experiencing molecular remission at completion of consolidation, clinical experience indicates that the risk of relapse is low; thus, PCR monitoring in these patients may be more appropriate in the context of a clinical trial.

For patients undergoing maintenance therapy, periodic monitoring is recommended for up to 2 years during maintenance to detect molecular relapse in patients with intermediate- or high-risk disease. At the current level of test sensitivity and specificity, a change in status from PCR-negative to PCR-positive should be confirmed through analysis of bone marrow samples in a reliable laboratory within 2 to 4 weeks. If molecular relapse is confirmed by a second positive test, patients should be treated for relapsed disease. If the second test is negative, maintenance therapy and frequent monitoring (eg, every 3 months for up to 2 years) may be considered to ensure that the patient remains PCR-negative. Testing should ideally be performed in the same laboratory to maintain a consistent level of assay sensitivity. For patients who develop cytopenias and have negative PCR results, a bone marrow biopsy is recommended to assess for new cytogenetic abnormalities, because secondary myelodysplastic syndromes and AML can rarely occur after treatment for APL.

**Conclusions**

These NCCN Guidelines Insights for AML highlight key updates to the management of patients with APL, focusing on the addition of a nonchemotherapy regi-

**References**

Acute Myeloid Leukemia, Version 2.2013


Instructions for Completion
To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/28080; and 4) view/print certificate. After reading the article, you should be able to answer the following multiple-choice questions. Credit cannot be obtained for tests completed on paper. You must be a registered user on NCCN.org. If you are not registered on NCCN.org, click on “New Member? Sign up here” link on the left hand side of the Web site to register. Only one answer is correct for each question. Once you successfully answer all posttest questions you will be able to view and/or print your certificate. Software requirements: Internet.

Posttest Questions
1. True or False: Although APL is a curable subtype of AML, hemorrhagic events caused by severe coagulopathy remain a primary cause of early death in these patients.
   a. True
   b. False

2. For patients with low- or intermediate-risk APL, which of the following induction treatment regimens are included in the NCCN Guidelines?
   a. ATRA + daunorubicin
   b. ATRA + cytarabine (AIDA regimen)
   c. ATRA + arsenic trioxide
   d. All of the above

3. True or False: Current published studies show that all patients with APL who experience molecular remission (PCR-negative status) after consolidation benefit from maintenance therapy.
   a. True
   b. False